{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T01:57:28Z","timestamp":1783562248999,"version":"3.55.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To evaluate angiographic findings in neonates up to 150 weeks postmenstrual age who received intravitreal ranibizumab for primary treatment of Type 1 retinopathy of prematurity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Retrospective evaluation of fluorescein angiogram findings was completed for 30 eyes of 16 neonates who received intravitreal ranibizumab as primary treatment for Type 1 retinopathy of prematurity between April 2013 and January 2015. Outcome measures included maturity to Zone III, vascular blunting, vascular loops, vascular dilatation, capillary dropout, and vascular fluorescein leakage.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Mean gestational age was 24<jats:sup>1\/7<\/jats:sup> weeks and mean postmenstrual age at time of intravitreal ranibizumab treatment was 35 weeks. Fluorescein angiograms performed at 44 weeks to 150 weeks postmenstrual age showed only 50% of eyes reached vascularization to Zone III; 40% had persistent vascular leakage; and \u226590% exhibited vascular blunting, vascular dilatation, and\/or capillary dropout.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Although intravitreal ranibizumab is effective in initial cessation of Type 1 retinopathy of prematurity, vascularization to Zone III was only achieved in 50% of eyes in our series and most eyes had fluorescein angiography evidence of vascular anomalies. If future studies are performed comparing treatment with laser photocoagulation to anti\u2013vascular endothelial growth factor, fluorescein angiographic studies should be considered to assess the status of the peripheral retinal vasculature to determine treatment effect.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000001996","type":"journal-article","created":{"date-parts":[[2018,1,3]],"date-time":"2018-01-03T20:58:31Z","timestamp":1515013111000},"page":"700-705","source":"Crossref","is-referenced-by-count":29,"title":["FLUORESCEIN ANGIOGRAPHIC EVALUATION OF PERIPHERAL RETINAL VASCULATURE AFTER PRIMARY INTRAVITREAL RANIBIZUMAB FOR RETINOPATHY OF PREMATURITY"],"prefix":"10.1097","volume":"39","author":[{"given":"C. Armitage","family":"Harper","sequence":"first","affiliation":[{"name":"Austin Retina Associates, Austin, Texas;"},{"name":"Department of Surgery and Perioperative Care, Dell Medical School at The University of Texas at Austin, Austin, Texas;"},{"name":"Department of Ophthalmology,University of Texas Health Science Center, San Antonio, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren M.","family":"Wright","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology,University of Texas Health Science Center, San Antonio, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan C.","family":"Young","sequence":"additional","affiliation":[{"name":"Austin Retina Associates, Austin, Texas;"},{"name":"Department of Ophthalmology,University of Texas Health Science Center, San Antonio, Texas;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah P.","family":"Read","sequence":"additional","affiliation":[{"name":"Bascom Palmer Eye Institute, Miami, Florida; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel Y.","family":"Chang","sequence":"additional","affiliation":[{"name":"Retina and Vitreous of Texas, Baylor University, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230816","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R2-20230816","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archopht.123.7.991","article-title":"The international classification of retinopathy of prematurity revisited","volume":"123","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"R4-20230816","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.jaapos.2012.12.017","article-title":"BEAT-ROP refraction data at age 2 years","volume":"17","author":"Geloneck","year":"2013","journal-title":"J AAPOS"},{"key":"R5-20230816","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jaapos.2009.12.002","article-title":"Avastin as monotherapy for retinopathy of prematurity","volume":"14","author":"Mintz-Hittner","year":"2010","journal-title":"J AAPOS"},{"key":"R6-20230816","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ajo.2009.05.031","article-title":"A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity","volume":"148","author":"Micieli","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"R7-20230816","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.ophtha.2016.06.055","article-title":"Chronic vascular arrest as a predictor of bevacizumab treatment failure in retinopathy of prematurity","volume":"23","author":"Toy","year":"2016","journal-title":"Ophthalmol"},{"key":"R8-20230816","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3928\/23258160-20161219-11","article-title":"Incomplete retinal vascularization after ranibizumab treatment of retinopathy of prematurity","volume":"48","author":"Day","year":"2017","journal-title":"Ophthalmol Surg Lasers Imaging Retina"},{"key":"R9-20230816","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3928\/23258160-20150422-05","article-title":"Primary intravitreal ranibizumab for high-risk retinopathy of prematurity","volume":"46","author":"Baumal","year":"2015","journal-title":"Ophthalmol Surg Lasers Imaging Retina"},{"key":"R10-20230816","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archophthalmol.2012.592","article-title":"Reactivation of retinopathy of prematurity after bevacizumab injection","volume":"130","author":"Hu","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"R11-20230816","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3928\/23258160-20160229-12","article-title":"Very late reactivation of retinopathy of prematurity after monotherapy with intravitreal bevacizumab","volume":"47","author":"Snyder","year":"2016","journal-title":"Ophthalmol Surg Lasers Imaging Retina"},{"key":"R12-20230816","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/IAE.0000000000000578","article-title":"Reactivation of retinopathy of prematurity after ranibizumab treatment","volume":"35","author":"Wong","year":"2015","journal-title":"Retina"},{"key":"R13-20230816","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","article-title":"Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings","volume":"121","author":"Lepore","year":"2014","journal-title":"Ophthalmology"},{"key":"R14-20230816","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/bjophthalmol-2013-304109","article-title":"Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity","volume":"98","author":"Tahija","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"R15-20230816","article-title":"Progressive retinal detachment in infants with retinopathy of prematurity treated with intravitreal bevacizumab or ranibizumab","author":"Yonekawa","year":"2017","journal-title":"Retina"},{"key":"R16-20230816","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1097\/IAE.0000000000001561","article-title":"Technique for infant intravitreal injection in treatment of retinopathy of prematurity","volume":"37","author":"Wright","year":"2017","journal-title":"Retina"},{"key":"R17-20230816","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1001\/archopht.1984.01040030908011","article-title":"An international classification of retinopathy of prematurity","volume":"102","year":"1984","journal-title":"Arch Ophthalmol"},{"key":"R18-20230816","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jaapos.2011.12.157","article-title":"Fluorescein angiography to estimate normal peripheral retinal nonperfusion in children","volume":"16","author":"Blair","year":"2012","journal-title":"J AAPOS"},{"key":"R19-20230816","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3928\/23258160-20170301-10","article-title":"Reactivation of retinopathy of prematurity three years after treatment with bevacizumab","volume":"48","author":"Hajrasouliha","year":"2017","journal-title":"Ophthalmol Surg Lasers Imaging Retina"},{"key":"R20-20230816","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00417-008-0786-7","article-title":"Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity","volume":"246","author":"Honda","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R21-20230816","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/eye.2009.156","article-title":"Paradoxical vascular-fibrotic reaction after intravitreal bevacizumab for retinopathy of prematurity","volume":"24","author":"Zepeda-Romero","year":"2010","journal-title":"Eye (Lond)"},{"key":"R22-20230816","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3 retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"R23-20230816","article-title":"Prophylactic peripheral laser and fluoroscien angiography after bevacizumab for retinopathy of prematurity","author":"Gonzalez","year":"2017","journal-title":"Retina"},{"key":"R24-20230816","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.ophtha.2015.04.023","article-title":"Influence of fluorescein angiography on the diagnosis and management of retinopathy of prematurity","volume":"122","author":"Klufas","year":"2015","journal-title":"Ophthalmology"},{"key":"R25-20230816","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/S0161-6420(01)00660-1","article-title":"Adult retinopathy of prematurity: outcomes of rhegmatogenous retinal detachments and retinal tears","volume":"108","author":"Kaiser","year":"2001","journal-title":"Ophthalmology"},{"key":"R26-20230816","first-page":"225","article-title":"Retinopathy of prematurity: late complications in the baby boomer generation (1946\u20131964)","volume":"103","author":"Smith","year":"2005","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R27-20230816","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00417-014-2857-2","article-title":"Aggressive posterior retinopathy of prematurity: a pilot study of quantitative analysis of vascular features","volume":"253","author":"Woo","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006982-201904000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:13:17Z","timestamp":1692231197000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006982-201904000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000001996","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]}}}